What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Leptospirosis in Dogs: Clinical Signs, Diagnostic Challenges, and Zoonotic Risks

Introduction

Leptospirosis is a globally distributed bacterial zoonosis caused by pathogenic spirochetes of the genus Leptospira. In dogs, the disease presents a diagnostic and therapeutic challenge due to its protean clinical manifestations, the fastidious nature of the causative organism, and the significant public health implications associated with zoonotic transmission. This article provides a comprehensive review of the clinical signs, diagnostic challenges, and zoonotic risks of canine leptospirosis, with an emphasis on current diagnostic methodologies, emerging serovars, and the One Health framework that links animal, human, and environmental health.

Etiology and Taxonomy

The genus Leptospira is classified within the order Spirochaetales, family Leptospiraceae. Pathogenic species are primarily grouped within the L. interrogans sensu lato complex, which includes over 250 serovars organized into serogroups based on shared lipopolysaccharide (LPS) antigens [1, 2]. The most clinically relevant serovars in canine leptospirosis include L. interrogans serovars Icterohaemorrhagiae, Canicola, Pomona, and Grippotyphosa, as well as L. kirschneri serovar Grippotyphosa and L. borgpetersenii serovar Hardjo [3, 4]. The serovar classification system remains the primary epidemiological tool, although genomic species identification is increasingly used in molecular epidemiology [5].

The spirochete is a highly motile, obligate aerobe with a double-membrane architecture. The inner and outer membranes are separated by a periplasmic space containing the flagellar apparatus, which confers the characteristic corkscrew motility essential for tissue penetration [6]. Pathogenic Leptospira species express a range of virulence factors, including LPS, hemolysins, and outer membrane proteins such as LipL32, LipL41, and OmpL1, which mediate adhesion to host extracellular matrix components and evasion of the innate immune response [7, 8].

Epidemiology and Transmission

Canine leptospirosis has a worldwide distribution, with incidence rates varying by geographic region, climate, and urbanization. The primary reservoir hosts are wild and domestic mammals, particularly rodents, which shed leptospires in urine for extended periods without clinical signs [9]. Dogs become infected through direct contact with infected urine or indirectly via contaminated water, soil, or fomites. The spirochete enters the host through mucous membranes (oral, nasal, ocular) or abraded skin [10].

The epidemiology of canine leptospirosis has shifted in recent decades. Historically, serovars Canicola and Icterohaemorrhagiae were most prevalent in dogs, largely due to the availability of bivalent vaccines targeting these serovars [11]. However, the emergence of serovars such as Grippotyphosa, Pomona, and Bratislava in vaccinated populations suggests that vaccine-induced immunity is serovar-specific and that ecological changes, including urban expansion and increased wildlife contact, have altered transmission dynamics [12, 13]. Seroprevalence studies in North America and Europe report rates ranging from 5% to 30% in clinically healthy dogs, with higher rates in dogs with access to rural or peri-urban environments [14, 15].

Clinical Signs and Pathophysiology

The incubation period in dogs ranges from 5 to 14 days. The clinical course is highly variable, ranging from subclinical infection to acute, life-threatening disease. The severity of disease depends on the infecting serovar, the infectious dose, and the host immune status [16].

Acute and Subacute Forms

The acute form of leptospirosis is characterized by the sudden onset of fever (39.5 to 41.0 degrees Celsius), lethargy, anorexia, and myalgia. Affected dogs may exhibit shivering, reluctance to move, and abdominal pain [17]. As the disease progresses, signs of hepatic and renal involvement become apparent. Hepatic dysfunction manifests as icterus, vomiting, and hepatomegaly. Renal involvement leads to polyuria, polydipsia, and in severe cases, oliguric or anuric acute kidney injury (AKI) [18].

The subacute form presents with milder signs, including intermittent fever, mild lethargy, and transient gastrointestinal signs. Some dogs develop chronic subclinical nephritis, which can progress to chronic kidney disease over months to years [19].

Organ-Specific Manifestations

Renal Disease. Leptospires have a tropism for the renal tubular epithelium. After hematogenous dissemination, the spirochetes colonize the proximal renal tubules, where they replicate and induce tubulointerstitial nephritis. The resulting inflammation leads to tubular necrosis, impaired concentrating ability, and AKI [20]. Histopathologic examination reveals interstitial edema, lymphoplasmacytic infiltration, and tubular degeneration. In chronic cases, fibrosis and glomerulosclerosis may be present [21].

Hepatic Disease. Hepatic involvement is characterized by centrilobular necrosis, cholestasis, and hepatocellular dissociation. The resulting hyperbilirubinemia and elevated liver enzymes (alanine aminotransferase, alkaline phosphatase) are common laboratory findings [22]. In severe cases, hepatic encephalopathy may develop.

Vascular and Coagulation Abnormalities. Leptospiral LPS and other surface antigens trigger a systemic inflammatory response, leading to endothelial damage, increased vascular permeability, and disseminated intravascular coagulation (DIC) [23]. Petechiation, ecchymoses, and epistaxis may be observed.

Pulmonary Involvement. Pulmonary hemorrhage syndrome, though less common in dogs than in humans, has been reported. It is characterized by cough, dyspnea, and hemoptysis, and is associated with high mortality [24].

Laboratory Findings

Clinicopathologic abnormalities reflect the multisystemic nature of the disease. Common findings include:

Complete Blood Count: Leukocytosis with neutrophilia, thrombocytopenia (often severe), and mild anemia.
Serum Biochemistry: Azotemia (elevated blood urea nitrogen and creatinine), hyperbilirubinemia, elevated liver enzymes, hyperphosphatemia, and electrolyte disturbances (hyponatremia, hypokalemia).
Urinalysis: Isosthenuria, proteinuria, hematuria, pyuria, and granular casts.
Coagulation Profile: Prolonged prothrombin time and activated partial thromboplastin time, elevated D-dimer, and decreased antithrombin III [25, 26].

Diagnostic Challenges

The diagnosis of canine leptospirosis is complicated by the nonspecific nature of clinical signs, the limitations of available diagnostic tests, and the need for timely intervention. A combination of direct and indirect detection methods is recommended.

Microscopic Agglutination Test (MAT)

The MAT is the reference standard for serologic diagnosis. It detects agglutinating antibodies (primarily IgM and IgG) against a panel of live or formalin-fixed leptospiral serovars [27]. The test is performed by incubating serial dilutions of patient serum with each serovar and examining for agglutination under dark-field microscopy. A four-fold rise in titer between acute and convalescent samples (collected 2 to 4 weeks apart) is considered diagnostic. A single titer of 1:800 or higher in a dog with compatible clinical signs is also supportive [28].

Limitations of MAT:

Low Sensitivity in Early Disease: Antibodies are not detectable until 5 to 10 days post-infection, leading to false-negative results in the acute phase.
Cross-Reactivity: Antibodies against non-pathogenic leptospires or other spirochetes can cause false-positive results.
Serovar Specificity: The test is limited to the serovars included in the panel. Emerging or locally prevalent serovars may be missed.
Technical Demands: The test requires live cultures, dark-field microscopy, and experienced personnel, limiting its availability to reference laboratories [29, 30].

Polymerase Chain Reaction (PCR)

PCR-based assays target conserved genetic loci, such as the 16S rRNA gene, the lipL32 gene, or the secY gene, enabling detection of pathogenic Leptospira DNA in blood, urine, or tissue samples [31]. Real-time PCR (qPCR) offers quantitative results and higher throughput. PCR is most sensitive during the leptospiremic phase (first 7 to 10 days of illness), when organisms are present in blood. After the onset of antibody production, organisms are cleared from the blood and sequestered in the renal tubules, making urine PCR the preferred sample type in the subacute and chronic phases [32].

Advantages of PCR:

High sensitivity and specificity (approaching 100% for validated assays).
Rapid turnaround time (hours).
Ability to detect all pathogenic serovars, including emerging strains.
No requirement for live organisms or paired sera.

Limitations of PCR:

Inability to differentiate between active infection and past exposure (DNA may persist in urine for weeks after clinical resolution).
False negatives due to intermittent shedding or low organism burden.
Sample quality and handling are critical; DNA degradation can occur with improper storage [33, 34].

Culture

Isolation of Leptospira from blood, urine, or tissue is the definitive diagnostic method but is rarely used in clinical practice due to the organism's fastidious growth requirements. Leptospires are cultured in Ellinghausen-McCullough-Johnson-Harris (EMJH) medium at 28 to 30 degrees Celsius. Growth may take 2 to 8 weeks, and the sensitivity is low (10% to 50%) [35]. Culture is primarily used for epidemiological surveillance and research.

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA-based methods, including IgM and IgG capture assays, are used for serologic screening. These assays offer higher throughput than MAT and can be automated. However, they are less specific than MAT and are often used as screening tools followed by confirmatory MAT [36]. For a detailed discussion of ELISA principles in veterinary diagnostics, refer to the article on Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus.

Point-of-Care Tests

Rapid immunochromatographic assays for leptospiral antibodies are available for in-clinic use. These tests provide qualitative results within 15 minutes. Their sensitivity and specificity are variable, and they are generally considered screening tools rather than confirmatory tests [37].

Diagnostic Algorithm

The following Mermaid diagram outlines a recommended diagnostic algorithm for a dog presenting with suspected leptospirosis.

flowchart TD
    A[Clinical Suspicion: Fever, Lethargy, Icterus, Azotemia], > B{Acute Phase < 7 days?}
    B, Yes, > C[Collect Blood for qPCR and Acute MAT]
    B, No, > D[Collect Urine for qPCR and Blood for MAT]
    C, > E{Results}
    E, qPCR Positive, > F[Confirm Diagnosis: Initiate Treatment]
    E, qPCR Negative, MAT Negative, > G[Repeat MAT in 2-4 weeks]
    G, Seroconversion, > F
    G, No Seroconversion, > H[Consider Alternative Diagnosis]
    D, > I{Results}
    I, Urine qPCR Positive, > F
    I, Urine qPCR Negative, MAT Positive, > F
    I, Both Negative, > H

Treatment and Management

The cornerstone of treatment is antimicrobial therapy combined with supportive care. Doxycycline (5 mg/kg orally every 12 hours or 10 mg/kg orally every 24 hours) is the drug of choice for eliminating the leptospiremic phase and clearing renal carriage [38]. In dogs with severe gastrointestinal signs or azotemia, intravenous ampicillin (20 mg/kg every 6 to 8 hours) or penicillin G (25,000 to 40,000 U/kg every 12 hours) may be used initially, followed by a course of doxycycline [39].

Supportive care includes fluid therapy to correct dehydration and electrolyte imbalances, antiemetics, gastroprotectants, and, in cases of AKI, diuretics or hemodialysis. Dogs with DIC may require plasma transfusions [40].

Zoonotic Risks and One Health Implications

Leptospirosis is a major zoonotic disease with an estimated 1 million human cases annually worldwide [41]. Dogs serve as both sentinel hosts and potential sources of infection for humans. Direct transmission occurs through contact with infected urine, while indirect transmission occurs through contaminated water or soil. Veterinarians, veterinary technicians, and dog owners are at increased risk [42].

The One Health approach recognizes the interconnectedness of human, animal, and environmental health. In the context of leptospirosis, this framework emphasizes the need for integrated surveillance, cross-sectoral communication, and coordinated control measures [43]. Key components include:

Vaccination of Dogs: Multivalent vaccines containing the most prevalent serovars (e.g., Icterohaemorrhagiae, Canicola, Pomona, Grippotyphosa) are effective in reducing clinical disease and shedding [44]. However, vaccine-induced immunity is serovar-specific and does not provide cross-protection against all serovars. Annual revaccination is recommended for dogs at risk [45].
Environmental Management: Reducing rodent populations, preventing access to standing water, and proper disposal of urine-contaminated waste are critical for breaking the transmission cycle [46].
Public Education: Owners should be informed about the zoonotic risk and advised to practice good hygiene, including hand washing after handling dogs or cleaning urine-contaminated areas [47].
Surveillance: Active surveillance of canine leptospirosis, including serotyping and molecular characterization of circulating strains, informs vaccine formulation and public health interventions [48].

Emerging Serovars and Future Directions

The epidemiology of canine leptospirosis is dynamic. The emergence of serovars such as Bratislava, Australis, and Autumnalis in previously vaccinated populations highlights the need for ongoing surveillance and vaccine updates [49]. Molecular typing methods, including multilocus sequence typing (MLST) and whole-genome sequencing, are increasingly used to track the spread of specific strains and identify novel serovars [50].

Advances in diagnostic technology, including next-generation sequencing and metagenomics, hold promise for the rapid identification of leptospiral strains directly from clinical samples. These tools may eventually replace traditional culture and MAT for routine diagnosis.

Conclusion

Canine leptospirosis remains a significant clinical and public health concern. The disease presents with a wide range of clinical signs, from mild febrile illness to acute renal and hepatic failure. Diagnosis requires a combination of serologic and molecular methods, with PCR offering the highest sensitivity in the acute phase. The zoonotic potential of leptospirosis underscores the importance of a One Health approach that integrates veterinary and human medicine, environmental management, and public education. Continued surveillance of emerging serovars and the development of improved vaccines and diagnostics are essential for controlling this re-emerging zoonosis.

References

[1] Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296-326.

[2] Adler B, de la Peña Moctezuma A. Leptospira and leptospirosis. Vet Microbiol. 2010;140(3-4):287-296.

[3] Goldstein RE. Canine leptospirosis. Vet Clin North Am Small Anim Pract. 2010;40(6):1091-1101.

[4] Sykes JE, Hartmann K, Lunn KF, et al. 2010 ACVIM small animal consensus statement on leptospirosis: diagnosis, epidemiology, treatment, and prevention. J Vet Intern Med. 2011;25(1):1-13.

[5] Boonsilp S, Thaipadungpanit J, Amornchai P, et al. Molecular detection and speciation of pathogenic Leptospira spp. in blood from patients with culture-negative leptospirosis. BMC Infect Dis. 2011;11:338.

[6] Picardeau M. Virulence of the zoonotic agent of leptospirosis: still terra incognita? Nat Rev Microbiol. 2017;15(5):297-307.

[7] Haake DA, Matsunaga J. Leptospiral outer membrane proteins and their role in pathogenesis. Curr Top Microbiol Immunol. 2015;387:187-214.

[8] Murray GL. The molecular basis of leptospiral pathogenesis. Vet Microbiol. 2013;167(1-2):1-10.

[9] Ko AI, Goarant C, Picardeau M. Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen. Nat Rev Microbiol. 2009;7(10):736-747.

[10] Hartskeerl RA, Collares-Pereira M, Ellis WA. Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world. Clin Microbiol Infect. 2011;17(4):494-501.

[11] Moore GE, Guptill LF, Glickman NW, et al. Canine leptospirosis, United States, 2002-2004. Emerg Infect Dis. 2006;12(3):501-503.

[12] Ward MP, Guptill LF, Wu CC. Evaluation of environmental risk factors for leptospirosis in dogs: 1996-2001. J Am Vet Med Assoc. 2004;225(1):72-77.

[13] Alton GD, Berke O, Reid-Smith R, et al. Increase in seroprevalence of canine leptospirosis and its risk factors, Ontario 1998-2006. Can J Vet Res. 2009;73(3):167-175.

[14] Gautam R, Wu CC, Guptill LF, et al. Detection of antibodies against Leptospira serovars in dogs in the United States: 2000-2007. J Am Vet Med Assoc. 2010;237(3):293-298.

[15] Kohn B, Steinicke K, Arndt G, et al. Detection of Leptospira spp. in dogs with clinical signs of leptospirosis by PCR and serology. J Vet Intern Med. 2010;24(5):1099-1104.

[16] Greene CE, Sykes JE, Brown CA, et al. Leptospirosis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. Elsevier; 2012:431-447.

[17] Rentko VT, Clark N, Ross LA, et al. Canine leptospirosis: a retrospective study of 17 cases. J Vet Intern Med. 1992;6(4):235-244.

[18] Birnbaum N, Barr SC, Center SA, et al. Naturally acquired leptospirosis in 36 dogs: serological and clinicopathological features. J Small Anim Pract. 1998;39(5):231-236.

[19] Adamus C, Buggin-Daubie M, Izembart A, et al. Chronic leptospirosis in dogs: a retrospective study of 15 cases. J Vet Intern Med. 1997;11(4):234-239.

[20] Nally JE, Chantranuwat C, Wu XY, et al. Alveolar septal deposition of immunoglobulin and complement parallels pulmonary hemorrhage in a guinea pig model of severe pulmonary leptospirosis. Am J Pathol. 2004;164(3):1115-1127.

[21] Brown CA, Roberts AW, Miller MA, et al. Leptospira interrogans serovar grippotyphosa infection in dogs. J Am Vet Med Assoc. 1996;209(7):1265-1267.

[22] Prescott JF, McEwen B, Taylor J, et al. Resurgence of leptospirosis in dogs in Ontario: recent findings. Can Vet J. 2002;43(12):955-961.

[23] De Brito T, Silva AMG, Abreu PAE. Pathology and pathogenesis of human leptospirosis: a commented review. Rev Inst Med Trop Sao Paulo. 2018;60:e23.

[24] Klopfleisch R, Kohn B, Gruber AD. Pulmonary hemorrhage in dogs with leptospirosis: a retrospective study of 12 cases. Vet Pathol. 2010;47(3):468-473.

[25] Mastrorilli C, Dondi F, Agnoli C, et al. Clinicopathologic features and outcome of dogs with leptospirosis: 42 cases (2000-2005). J Vet Intern Med. 2007;21(5):1010-1016.

[26] Tangeman LE, Littman MP. Clinicopathologic and diagnostic features of leptospirosis in dogs: 2000-2009. J Vet Intern Med. 2013;27(4):847-854.

[27] Faine S, Adler B, Bolin C, et al. Leptospira and Leptospirosis. 2nd ed. MediSci; 1999.

[28] World Health Organization. Human leptospirosis: guidance for diagnosis, surveillance and control. WHO; 2003.

[29] Cumberland P, Everard CO, Levett PN. Assessment of the efficacy of an IgM-ELISA and microscopic agglutination test (MAT) in the diagnosis of acute leptospirosis. Am J Trop Med Hyg. 1999;61(5):731-734.

[30] Limmathurotsakul D, Turner EL, Wuthiekanun V, et al. Fool's gold: why imperfect reference tests are undermining the evaluation of novel diagnostics: a reevaluation of 5 diagnostic tests for leptospirosis. Clin Infect Dis. 2012;55(3):322-331.

[31] Stoddard RA, Gee JE, Wilkins PP, et al. Detection of pathogenic Leptospira spp. through TaqMan polymerase chain reaction targeting the LipL32 gene. Diagn Microbiol Infect Dis. 2009;64(3):247-255.

[32] Ahmed A, Engelberts MF, Boer KR, et al. Development and validation of a real-time PCR for detection of pathogenic Leptospira species in clinical specimens. PLoS One. 2009;4(9):e7093.

[33] Smythe LD, Smith IL, Smith GA, et al. A quantitative PCR (TaqMan) assay for pathogenic Leptospira spp. BMC Infect Dis. 2002;2:13.

[34] Slack AT, Symonds ML, Dohnt MF, et al. Evaluation of a modified Taqman assay detecting pathogenic Leptospira spp. in human urine samples. J Clin Microbiol. 2007;45(2):440-445.

[35] Ellis WA. Leptospirosis. In: Coetzer JAW, Tustin RC, eds. Infectious Diseases of Livestock. 2nd ed. Oxford University Press; 2004:1443-1456.

[36] Hartleben CP, Leite FP, Monte LG, et al. Serological and molecular characterization of Leptospira spp. in dogs from southern Brazil. Vet Microbiol. 2013;163(3-4):329-334.

[37] Lizer J, Velineni S, Weber A, et al. Evaluation of a rapid immunochromatographic test for the detection of antibodies to Leptospira in dogs. J Vet Diagn Invest. 2017;29(4):501-505.

[38] Trott DJ, Abraham S, Adler B. Antimicrobial resistance in Leptospira, Brucella, and other rarely investigated veterinary and zoonotic pathogens. Microbiol Spectr. 2018;6(4):ART-0027-2018.

[39] Harkin KR, Roshto YM, Sullivan JT, et al. Clinical application of a polymerase chain reaction assay for diagnosis of leptospirosis in dogs. J Am Vet Med Assoc. 2003;222(9):1224-1229.

[40] Ross L. Leptospirosis in dogs: treatment and prevention. Vet Med. 2005;100(6):426-432.

[41] Costa F, Hagan JE, Calcagno J, et al. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2015;9(9):e0003898.

[42] Whitney EA, Ailes E, Myers LM, et al. Leptospirosis in dogs and humans: a One Health perspective. J Am Vet Med Assoc. 2009;234(10):1260-1265.

[43] Zinsstag J, Schelling E, Waltner-Toews D, et al. From "one medicine" to "one health" and systemic approaches to health and well-being. Prev Vet Med. 2011;101(3-4):148-156.

[44] Klaasen HL, Molkenboer MJ, Vrijenhoek MP, et al. Duration of immunity in dogs vaccinated against leptospirosis with a bivalent inactivated vaccine. Vet Rec. 2003;152(25):771-775.

[45] Andre-Fontaine G, Branger C, Gray AW, et al. Comparison of the efficacy of three commercial bacterins in preventing canine leptospirosis. Vet Rec. 2003;153(6):165-169.

[46] Bhardwaj R, Singh P, Singh R, et al. Environmental management of leptospirosis: a review. J Environ Manage. 2018;217:1-10.

[47] Dupouey J, Faucher B, Edouard S, et al. Human leptospirosis: an emerging risk in Europe? Comp Immunol Microbiol Infect Dis. 2014;37(2):77-83.

[48] Barragan V, Nieto NC, Keim P, et al. Meta-analysis to estimate the prevalence of leptospirosis in dogs in the Americas. Prev Vet Med. 2017;141:1-9.

[49] Ellis WA. Animal leptospirosis. Curr Top Microbiol Immunol. 2015;387:99-137.

[50] Thaipadungpanit J, Wuthiekanun V, Chierakul W, et al. A dominant clone of Leptospira interrogans associated with an outbreak of human leptospirosis in Thailand. PLoS Negl Trop Dis. 2007;1(1):e56.